| Drug ID: | Drug174 |
|---|---|
| Drug Name: | Cyclic GMP |
| CID: | 135398570 |
| DrugBank ID: | DB02315 |
| Modality: | Small Molecule |
| Groups: | experimental |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT01534312 |
| Molecular Formula: | C10H12N5O7P |
| Molecular Weight: | 345.21 g/mol |
| Isomeric SMILES: | C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=C(NC4=O)N)O)OP(=O)(O1)O |
| Synonyms: | cyclic gmp; 3',5'-cyclic GMP; cyclic-GMP; Cyclic 3',5'-GMP; CHEBI:16356; UNII-H2D2X058MU; Cyclic 3',5'-guanylic acid; H2D2X058MU; C-GMP; EINECS 231-641-6 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1266 | 135398570 | Cyclic GMP | 5138 | PDE2A | Homo sapiens (human) | Inhibitor | |
| dt1267 | 135398570 | Cyclic GMP | 610 | HCN2 | Homo sapiens (human) | 10592235 | None |
| dt1268 | 135398570 | Cyclic GMP | 5573 | PRKAR1A | Homo sapiens (human) | 10592235 | None |
| dt1269 | 135398570 | Cyclic GMP | 9356 | SLC22A6 | Homo sapiens (human) | 9228014 | None |
| dt1270 | 135398570 | Cyclic GMP | 351 | APP | Homo sapiens (human) | 10222124 | APP protein alternative form results in decreased abundance of cyclic GMP |
| dt1271 | 135398570 | Cyclic GMP | 5146 | PDE6C | Sus scrofa (pig) | 18669600 | PDE6C protein results in increased degradation of cyclic GMP |
| dt1272 | 135398570 | Cyclic GMP | 4878 | NPPA | Rattus norvegicus (Norway rat) | 12972712 | Puromycin aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of cyclic GMP] |
| dt1273 | 135398570 | Cyclic GMP | 623 | BDKRB1 | Rattus norvegicus (Norway rat) | 16982965 | [bradykinin, leu(8)-des-arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [valsartan results in increased abundance of cyclic GMP] |
| dt1274 | 135398570 | Cyclic GMP | 186 | AGTR2 | Rattus norvegicus (Norway rat) | 16982965 | [PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [valsartan results in increased abundance of cyclic GMP] |
| dt1275 | 135398570 | Cyclic GMP | 207 | AKT1 | Rattus norvegicus (Norway rat) | 12891555 | AKT1 protein inhibits the reaction [carbon tetrachloride results in decreased abundance of cyclic GMP] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05916274 | Exploration of the Activity of DNA Located Outside of Cellular Nucleus to Amplify Inflammation in Inflammatory Bowel Disease in Children Through Biological Pathway Cyclic GMP-AMP Synthase (cGAS) - Stimulator of Interferon Genes (STING) | None | COMPLETED | Centre Hospitalier Rgional d'Orlans | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | BIOLOGICAL: Blood and fecal samples|PROCEDURE: Co… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations